Quantum Pharmaceutical appoints commercial director

Victoria Buyer has 10 years of industry experience

Quantum Pharmaceutical, a UK-based pharmaceutical specials manufacturer, has appointed Victoria Buyer as commercial director.

With a decade’s industry experience, Buyer has previously been responsible for the growth and development of companies including GlaxoSmithKline and Alliance UniChem.

Buyer said: ‘Quantum already strives to ensure its operations are at the forefront of the marketplace – and I’m determined to build on its strong foundations and forge links with new partners while reinforcing collaboration with our loyal customer network.’

You may also like

Containment
Quantum Pharmaceutical opens aseptic manufacturing facility

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing
Quantum Pharmaceutical moves into new HQ

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
Manufacturing
The 7 most common process development mistakes

The 7 most common process development mistakes

At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
Manufacturing
What are injectable hydrogel microspheres?

What are injectable hydrogel microspheres?

The demand for longer-lasting therapies is accelerating innovation in injectable drug delivery, driven by the need to maintain stable therapeutic levels while minimising repeated administration
Manufacturing
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Subscribe now